A lazy day yesterday just catching up with all the computer work and housework.
We went to Tesco where I bought all new bedding for the bed settee ready for our son and DIl to visit. Ray took Louis for a walk.
Louis was in a real funny mood last night I think he knows I have booked him into kennels in Oct ??
Even when i went to bed I had to get up as my legs were so sore. The bilateral leg oedema is very sore now. I turn over in bed and the skin gets rubbed so i will have to wrap it up at night with loads of cream on it. i will chat to the Doc on Tuesday about it.
Just as I get it all nicely back to normal I damage it again.
I also had to take more painkillers as the side porthole is sore and that’s where the most pain is. It just niggles away and when i lay on the left side it causes it to be uncomfortable.
I had a message from a husband of a warrior that we she had died. So sad but it amazed me that even in grief he could think of telling me. We have such a bond together in the Mesowarrior community.
Sandra, who’s battled with Meso since diagnosis November 2012 passed away very peacefully at St Wilfrids Hospice on Friday 15th August. She is already so missed by jack, 23, Zoe 20 yrs old and family.
Two very interesting articles
One area of interest for many pharma companies is the potential for immunotherapies – drugs that encourage the body’s immune system to tackle a disease. The likes of Bristol-Myers Squibb and Merck Serono have made recent investments in the area, while AZ’s interests include MEDI4736, an anti-PD-L1 monoclonal antibody (mAb) in phase 2 trials for NSCLC, and tremelimumab, an anti-CTLA4 MAb in phase 2 for the rare cancer mesothelioma.
“These drugs are going to have activity in many different cancer types but there are many questions we still need to address,” said Galbraith, acknowledging struggles for some pharma companies working in the field. “There is much to be done in that space to understand better the optimal way to combine these drugs to their best effect. But I think it’s clear already that this a very important area of biology.”
And again, matching drugs that work well together will be crucial going forward: “Combination treatment will be a critical component; how best to put these drugs together with other checkpoint inhibitors, or with other agents that might affect a different part of the immune system, or with small molecules.”
The one to interest us mesowarriors as this is my drug being combined so like chemos we have now got the progress of 2 together. A doctor at one of the conferences told us this was the way to go and now its happening at last.
The partnership will see the two companies study a combination of BMS’ anti-PD1 drug Opdivo (nivolumab) and Celenge’s cancer drug Abraxane (paclitaxel).
The combination will be investigated in a phase I study across multiple tumour types, including HER-2 negative metastatic breast cancer, pancreatic cancer and non-small cell lung cancer.
“Through this collaboration, Bristol-Myers Squibb and Celgene will work together to advance the science and understanding of how the body’s own immune system and chemotherapy might work together to fight cancer,” said Michael Giordano, senior VP, oncology development, BMS.
Many companies are turning to cancer immunotherapies as the next advance in oncology treatment, with much of the focus on anti-PD1 therapies. Companies that have promising candidates in this class include Merck & Co with the highly promising pembrolizumab, Merck Serono with MSB0010718C and AstraZeneca with MEDI4736.
BMS remains to only company to have an anti-PD1 therapy approved in any country in the world, however, following the decision by regulators in Japan to recommend Opdivo as a treatment for patients with melanoma that is not treatable with surgery.
Opdivo’s rivals are not far behind – Merck & Co’s pembrolizumab is under review in Europe – and the potential for a combination treatment with Abraxane could give BMS a vital edge in the anti-PD1 race.
Positive study results would also benefit Celgene, which currently markets Abraxane as a treatment for pancreatic cancer and metastatic breast cancer.
The phase I trial is expected to begin in the fourth quarter of 2014 and will be conducted by Celgene. Different combinations will be tested in different indications: patients with HER-2 negative breast cancer receive Abraxane and Opdivo; patients with NSCLC will receive Abraxane, carboplatin and Opdivo; and patients with pancreatic adenocarcinoma will be treated with Abraxane, gemcitabine and Opdivo.
Markus Renschler, global head of haematology and oncology medical affairs, Celgene, said: “We believe that Abraxane is appropriate as a combination partner for novel immuno-oncology therapies due to its proven anti-tumour activity and that it can be administered without steroid premedication.”
Additional details of the collaboration were not disclosed.